Performance Comparison of Microfluidic and Immunomagnetic Platforms for Pancreatic CTC Enrichment
November 15, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Rydapt
(United States) [Available]Synonyms :
midostaurin
Class :
Antineoplastic agent and Tyrosinase Kinase Inhibitor
Brand Name :
Rydapt
(United States) [Available]Synonyms :
midostaurin
Class :
Antineoplastic agent and Tyrosinase Kinase Inhibitor
Adult
Dosage forms & Strengths:
Capsule
25mg
50 mg orally twice daily from the 8th to the 21st day of the cycle
Use the drug in combination with standard daunorubicin and cytarabine
The dose should be taken with food
midostaurin is indicated for patients having aggressive systemic mastocytosis, mast cell leukemia, or neoplasm-associated systemic mastocytosis
100 mg of the drug is given orally twice daily with meals
Note:
Before initiating the medication, administer antiemetics to prevent the risk of vomiting and nausea
Dose Adjustments
When the platelet count <50 x 10^9/L
Interrupt the dosing until platelet count reaches more than 50 x 10^9/L, later resume at 50 mg twice daily; if tolerated, increase the dose to 100 mg twice daily
Discontinue if decreased platelet count persists for more than 21 days and is suspected to be related to midostaurin
When hemoglobin <8 g/L
Interrupt the dosing until hemoglobin reaches more than 8 g/L, later resume at 50 mg twice daily; if tolerated, increase the dose to 100 mg twice daily
Discontinue the dose if the lower platelet count persists for more than 21 days and is related to midostaurin
Safety and efficacy not established.
Refer to the adult dosing
midostaurin is contraindicated in the patients who are hypersensitive to any of the excipients in the formulation
midostaurin: they may increase the QTc-prolonging effect of QTc-prolonging Agents
midostaurin: they may increase the QTc-prolonging effect of QTc-prolonging Agents
midostaurin: they may increase the QTc-prolonging effect of QTc-prolonging Agents
midostaurin: they may increase the QTc-prolonging effect of QTc-prolonging Agents
midostaurin: they may increase the QTc-prolonging effect of QTc-prolonging Agents
midostaurin is contraindicated in the patients who are hypersensitive to any of the excipients in the formulation
may enhace the serum concentration of each other when it is combined
may enhace the serum concentration of each other when it is combined
may enhace the serum concentration of each other when it is combined
may enhace the serum concentration of each other when it is combined
may enhace the serum concentration of each other when it is combined
may increase the serum concentration of each other when it is combined
may increase the serum concentration of each other when it is combined
may increase the serum concentration of each other when it is combined
may increase the serum concentration of each other when it is combined
abametapir increases the effect or level of midostaurin by altering the CYP3A4 enzyme metabolism
atazanavir increases the effect or level of midostaurin by altering the CYP3A4 enzyme metabolism
bosentan decreases the effect or level of midostaurin by altering the CYP3A4 enzyme metabolism
midostaurin and ceritinib, when used simultaneously, increase the QTc level
midostaurin and crizotinib, when used simultaneously, increase the QTc level
midostaurin and desflurane, when used simultaneously, increase the QTc level
midostaurin and entrecitinib, when used simultaneously, increase the QTc level
midostaurin and fingolimod, when used simultaneously, increase the QTc level
midostaurin and gilteritinib, when used simultaneously, increase the QTc level
idelalisib increases the effect or level of midostaurin by altering the CYP3A4 enzyme metabolism
ketoconazole increases the effect or level of midostaurin by altering the CYP3A4 enzyme metabolism
nelfinavir increases the effect or level of midostaurin by altering the CYP3A4 enzyme metabolism
oxcarbazepine decreases the effect or level of midostaurin by altering the CYP3A4 enzyme metabolism
phenytoin decreases the effect or level of midostaurin by altering the CYP3A4 enzyme metabolism
ritonavir increases the effect or level of midostaurin by altering the CYP3A4 enzyme metabolism
voriconazole increases the effect or level of midostaurin by altering the CYP3A4 enzyme metabolism
CYP3A strong enhancers of the small intestine may reduce the bioavailability of midostaurin
when used together, entrectinib and midostaurin both increase the QTc interval
when used together, encorafenib and midostaurin both increase the QTc interval
midostaurin and gilteritinib, when used in combination, increase the QTc interval
midostaurin and arformoterol, when used simultaneously, increase the QTc level
duvelisib increases the effect or level of midostaurin by altering the CYP3A4 enzyme metabolism
fedratinib increases the effect or level of midostaurin by altering the CYP3A4 enzyme metabolism
lorlatinib decreases the effect or level of midostaurin by altering the CYP3A4 enzyme metabolism
stiripentol decreases the effect or level of midostaurin by altering the CYP3A4 enzyme metabolism
midostaurin: they may diminish the serum concentration of CYP3A4 Inducers
midostaurin: they may diminish the serum concentration of CYP3A4 Inducers
midostaurin: they may diminish the serum concentration of CYP3A4 Inducers
midostaurin: they may diminish the serum concentration of CYP3A4 Inducers
midostaurin: they may diminish the serum concentration of CYP3A4 Inducers
When midostaurin is used together with ridaforolimus, this leads to enhanced concentration serum of midostaurin
when both drugs are combined, there may be a decreased metabolism of vinblastine
the effect of midostaurin is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
may increase the arrhythmogenic effect of Inhalational Anaesthetics
It may diminish the metabolism when combined with Melatonin
It may diminish the metabolism when combined with Melatonin
It may diminish the metabolism when combined with Melatonin
It may diminish the metabolism when combined with Melatonin
It may enhance the risk of adverse effects when combined with protein kinase inhibitors
It may enhance the risk of adverse effects when combined with protein kinase inhibitors
It may enhance the risk of adverse effects when combined with protein kinase inhibitors
It may enhance the risk of adverse effects when combined with protein kinase inhibitors
It may enhance the risk of adverse effects when combined with protein kinase inhibitors
The activity of WT and/or mutant FLT3 tyrosine kinases, VEGFR2, KIT, PDGFR, and protein kinase C alpha (PKCalpha) is inhibited by midostaurin and its main active metabolites.
Apoptosis of target leukemia cells expressing target receptors and mast cells is induced by inhibition of FLT3 receptor signaling cascades, which also has antiproliferative effects on a various cancer cell type.
Preliminary in vitro research indicates that midostaurin also interacts with the organic anion transporter (OATP) 1A1 and multidrug resistance protein (MRP)-2.
Frequency defined
>10%
Nausea
Febrile neutropenia
Hypocalcemia
Increased ALT
Mucositis
Vomiting
Headache
Petechiae
Musculoskeletal pain
Epistaxis
Device-related infection
Hypernatremia
Upper respiratory tract infection
Hyperglycemia
Increased ALT
Hemorrhoids
Arthralgia
Hyperhidrosis
Prolonged aPTT
Renal insufficiency
Insomnia
1-10%
Hyperuricemia
Hypertension
Cellulitis
Fungal infection
Dry skin
Weight increased
Pleural effusion
Thrombosis
Tremor
Pericardial effusion
Hypercalcemia
Eyelid edema
None
Contraindication:
Hypersensitivity
Caution:
Pulmonary Toxicity
QT Prolongation
Myelosuppression
Embryo-Fetal Toxicity
Pregnancy Warnings:
Pregnancy category: N/A
Lactation: Excretion in human breastmilk is unknown
Pregnancy categories:
Category A: Satisfactory and well-controlled studies show no evidence of risk to the fetus in the first trimester or in the later trimester.
Category B: No evidence of risk to fetus found in animal reproduction studies and there are not enough studies on pregnant women.
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for an effect in humans, care must be taken for potential risks in pregnant women.
Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite potential risks may be used only in emergency cases for potential benefits.
Category X: Drugs listed in this category clearly outweigh risks over benefits. These category drugs should be prohibited for pregnant women.
Category N: There is no data available for the drug under this category.
Pharmacology:
midostaurin inhibits the activity of multiple receptor tyrosine kinases by binding to their ATP-binding sites, preventing their autophosphorylation and downstream signaling pathways. This leads to decreased cell proliferation, induction of apoptosis, and inhibition of angiogenesis.
Pharmacodynamics:
The pharmacodynamics of midostaurin refers to the drug’s effects on the body and its mechanism of action. midostaurin is a small molecule inhibitor that selectively inhibits multiple receptor tyrosine kinases, including FMS-like tyrosine kinase 3 (FLT3), KIT, and platelet-derived growth factor receptor (PDGFR).
Pharmacokinetics:
Absorption
The peak plasma is achieved in 1-3 hours (single fasting dose) and 2.5-3 hours (with food)
Distribution
Protein-bound is more than 99.8%
The volume of distribution is 95.2 L
Metabolism
midostaurin undergoes primary metabolism by CYP3A4
Elimination and Excretion
The half-life is 21 hours for midostaurin; 32 hours (CGP62221) and 482 hours (CGP52421)
The systemic clearance rate is 14.9 L/hr
The drug is excreted 95% in feces and 4% in urine
Midostaurin is available in the form of oral capsules, and it is taken with food.
The drug should be swallowed whole, and the capsules should not be opened, chewed, crushed.
Missed doses:
If a dose of midostaurin is missed, administer it as soon as possible unless it is within 12 hours of the next dose.
In this case, the missed dose should be skipped, and the next dose should be taken at the usual time.
Patient information leaflet
Generic Name: midostaurin (Rx)
Pronounced: MYE-doe-STAW-rin
Why do we use midostaurin?
Midostaurin is used for the treatment of several types of cancers, including advanced systemic mastocytosis (ASM) and acute myeloid leukemia (AML).
It is studied for treatment in adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), mast cell leukemia (MCL), or high-risk acute myeloid leukemia (AML) who have a FLT3 mutation.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
